Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00063219 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

A Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
13
Study locations

NCT00063219 is a Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 48 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (85% lower). The trial reports 13 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00063219, a Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
13
Study locations

Study Summary

This non-randomized, open-label clinical trial is designed to determine safety and clinical activity of a new chemotherapeutic agent, MAC-321, when given intravenously to patients with non-small cell lung cancer. Clinical activity will be evaluated by determining the percentage of patients with an objective tumor response after treatment with MAC-321. Patients must have been previously treated with a platinum-containing chemotherapy regimen. A total of 96 patients will be enrolled in this trial. Eligible patients will receive MAC-321 intravenously every 3 weeks for up to a total of 6 courses of treatment. All patients will receive MAC-321 at the same dose. MAC-321 is an experimental drug, and is not offered outside of this research trial.

Conditions Studied

Carcinoma, Non-Small Cell Lung Lung Neoplasms

Interventions

  • DRUG MAC-321

Study Locations (13)

Pennsylvania

  • - Philadelphia
  • - Pittsburgh

California

  • - Los Angeles

Kentucky

  • - Lexington

Maryland

  • - Baltimore

Massachusetts

  • - Worcester

Minnesota

  • - Minneapolis

Missouri

  • - St Louis

New York

  • - New York

Trial Details

FieldValue
Enrollment Target 48 participants
Est. Completion 2005-02
Phase Phase 2

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00063219

The ClinicalTrials.gov registry entry for NCT00063219 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (85% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which MAC-321 is the first listed.

NCT00063219 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Pennsylvania, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT00063219 about?

NCT00063219 is a clinical study titled "Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy". This non-randomized, open-label clinical trial is designed to determine safety and clinical activity of a new chemotherapeutic agent, MAC-321, when given intravenously to patients with non-small cell lung cancer. Clinical activity will be evaluated by determining the percentage of patients with an o...

What is the current status of trial NCT00063219?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. Estimated completion is 2005-02.

What conditions does trial NCT00063219 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Lung Neoplasms.

What interventions are being tested in trial NCT00063219?

The interventions under investigation include: MAC-321 (DRUG).

Who is sponsoring clinical trial NCT00063219?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00063219 being conducted?

This trial has 13 study locations across California, Kentucky, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Lung Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.